Arcturus teams up with Thermo Fisher on mRNA therapy

• Arcturus Therapeutics (NASDAQ:ARCT) entered a collaboration with Thermo Fisher Scientific to support Phase 3 development of ARCT-032.
• The partnership covers manufacturing, clinical research, and potential commercialization for a cystic fibrosis mRNA therapy.
• Thermo Fisher will receive commercial manufacturing rights if ARCT-032 receives regulatory approval.

Arcturus Therapeutics Holdings (NASDAQ:ARCT) announced a strategic collaboration with Thermo Fisher Scientific (NYSE:TMO) to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.

The agreement integrates Thermo Fisher’s Accelerator™ Drug Development services, combining manufacturing, clinical research, and commercial readiness capabilities.

Arcturus said the partnership is intended to support advancement of ARCT-032 through Phase 3, subject to successful Phase 2 results.

Thermo Fisher will provide manufacturing and clinical trial support through its PPD™ clinical research business and broader CDMO infrastructure.

If regulatory approval is granted, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate agreement.

Arcturus said the collaboration is designed to streamline development and prepare supply capacity for potential commercialization of the cystic fibrosis treatment.